预约演示
更新于：2025-02-17
Tamsulosin Hydrochloride
盐酸坦洛新
更新于：2025-02-17
概要
基本信息
简介坦索罗辛于1997年在美国被批准用于医疗用途。具体而言，它是一种α1肾上腺素能受体阻滞剂。 以 Flomax 等品牌名称销售的坦索罗辛是一种用于治疗症状性良性前列腺增生 (BPH) 和慢性前列腺炎并帮助排出肾结石的药物。 当结石较大时，肾结石获益的证据更好。 它是通过嘴巴服用的。 常见的副作用包括头晕、头痛、失眠、恶心、视力模糊和性问题。 其他副作用可能包括站立时头晕目眩和血管性水肿。 坦索罗辛是一种α受体阻滞剂，通过放松前列腺肌肉起作用。坦索罗辛于1997年在美国被批准用于医疗用途。具体而言，它是一种α1肾上腺素能受体阻滞剂。 以 Flomax 等品牌名称销售的坦索罗辛是一种用于治疗症状性良性前列腺增生 (BPH) 和慢性前列腺炎并帮助排出肾结石的药物。 当结石较大时，肾结石获益的证据更好。 它是通过嘴巴服用的。 常见的副作用包括头晕、头痛、失眠、恶心、视力模糊和性问题。 其他副作用可能包括站立时头晕目眩和血管性水肿。 坦索罗辛是一种α受体阻滞剂，通过放松前列腺肌肉起作用。 |
药物类型 小分子化药 |
别名 (-)-tamsulosin、(R)-(-)-tamsulosin、(R)-5-(2-((2-(2-ethoxyphenoxy)ethyl)amino)propyl)-2-methoxybenzenesulfonamide + [36] |
靶点 |
作用机制 α1A-AR拮抗剂(肾上腺素能受体α-1a拮抗剂) |
最高研发阶段批准上市 |
首次获批日期 日本 (1993-07-02), |
最高研发阶段(中国)批准上市 |
特殊审评优先审评 (中国) |
登录后查看时间轴
结构/序列
分子式C20H29ClN2O5S |
InChIKeyZZIZZTHXZRDOFM-XFULWGLBSA-N |
CAS号106463-17-6 |
关联
311
项与 盐酸坦洛新 相关的临床试验NCT06803030
A Comparative Study on the Efficacy of Tamsulosin, Solifenacin and Mirabegron in Alleviating Ureteral Stent-related Symptoms: a Randomized Controlled Trial
NCT06737016
Efficacy and Safety of Tamsulosin, a Selective Alpha-1 Adrenergic Blocker, for Children with Posterior Urethral Valve: a Randomized Controlled Trial
NCT06262048
Prevention of Post Operative Urinary Retention After Thoracic Surgery: A Phase II Feasbility Trial
100 项与 盐酸坦洛新 相关的临床结果
登录后查看更多信息
100 项与 盐酸坦洛新 相关的转化医学
登录后查看更多信息
100 项与 盐酸坦洛新 相关的专利（医药）
登录后查看更多信息
3,174
项与 盐酸坦洛新 相关的文献（医药）2025-03-01Radiology case reports
Zinner syndrome unveiled: Ectopic ureter and seminal vesicle cyst leading to urinary dysfunction: A case report
Article
作者: Khamaysa, Jehad ; Dibas, Jana ; Dibas, Yazan ; Hattab, Moath ; Daraghmeh, Muath ; Rub, Adel Abu Al ; Sawafta, Khaled ; Sawaftah, Zaid ; Sawafta, Omar ; Rajha, Humam Emad
Zinner syndrome (ZS) is a rare congenital urological condition characterized by a triad of ipsilateral seminal vesicle cysts, unilateral renal agenesis, and ejaculatory duct obstruction, first described in 1914. This case report details the presentation and management of a 27-year-old male diagnosed with ZS following a 2-month history of urinary frequency, hesitancy, dysuria, and painful ejaculation. Physical examination revealed a left lower abdominal mass, and imaging confirmed the classic findings of ZS, including unilateral renal agenesis, an enlarged seminal vesicle cyst, and an ectopic ureter. Conservative treatment with tamsulosin initially improved symptoms, but due to the cyst's large size and the risk of complications, laparoscopic excision was recommended for definitive management. ZS is often diagnosed late due to nonspecific symptoms, with an average diagnosis age of 29.35 years. MRI is the gold standard for diagnosis, revealing seminal vesicle cysts, renal agenesis, and ejaculatory duct obstruction. Conservative management is reserved for asymptomatic cases, while symptomatic patients benefit from surgical intervention. This case emphasizes the importance of timely imaging, particularly in patients with nonspecific lower urinary tract symptoms, and highlights the role of tamsulosin as an effective interim therapy before definitive surgical treatment. The case underscores the need for clear diagnostic criteria and treatment pathways to improve outcomes in this rare condition, which can lead to infertility if not managed appropriately.
2025-03-01EUROPEAN JOURNAL OF PHARMACOLOGY
Ondansetron alleviates testosterone-induced BPH in rats through cross regulation of the 5-HT/AR/P-STAT3 and the non-canonical NF-κB pathways
Article
作者: Mohamed, Reem A ; Shouman, Maha M
Benign prostatic hyperplasia (BPH) is a widespread age-related health issue. Every year, new pathological cues are revealed in the pathogenesis of BPH, however, the role of serotonin, Janus tyrosine kinase (JAK)-2/ signal transducer and activator of the transcription (STAT)-3 and non-canonical nuclear factor-kappa B (NF-κB p52) pathways and their interaction with the androgen receptor (AR) in BPH are still not fully investigated. Accordingly, the aim of the current study was to unveil the possible modulatory effect of ondansetron alone and in combination with tamsulosin on these pathways and their utilization as therapeutic targets. Five groups of rats were utilized; group 1 received corn oil to serve as normal control, while the other groups administered testosterone (3 mg/kg, subcutaneously) dissolved in corn oil for 2 weeks followed by the co-administration of either tamsulosin (0.2 mg/kg, orally), ondansetron (2 mg/kg, intraperitoneally) or their combination for another 15 days along with testosterone injections. All treatments improved kidney function (creatinine and blood urea nitrogen), decreased oxidative stress (reduced glutathione and malondialdehyde), attenuated inflammation (NF-κB, cyclooxygenase-2), decreased AR expression, NF-κB p52, P-STAT3, transforming growth factor beta-1 in addition to markers of epithelial-mesenchymal transition (alpha smooth muscle actin and vimentin) this was associated with an increase in the prostatic content of serotonin, improvement in the histopathological picture and overall shrinkage in relative prostate weight. These results show that ondansetron is a very promising treatment for BPH especially in combination with tamsulosin and unveiled NF-κB p52 and serotonin as novel therapeutic targets in the management of BPH.
2025-03-01AMERICAN JOURNAL OF OPHTHALMOLOGY
The Effect of Tamsulosin on Iris Morphology, Ciliary Muscle Thickness, and Pupil Diameter
Article
作者: Öztürk, Caner ; Cevher, Selim ; Duran, Mustafa ; Ekici, Musa
PURPOSE:
To investigate the effect of tamsulosin on iris morphology, ciliary muscle thickness (CMT), pupil diameter (PD), and pupil responses to light using anterior segment optical coherence tomography and corneal topography.
DESIGN:
Prospective clinical before-and-after study METHODS: The right eyes of 43 patients with newly diagnosed benign prostatic hyperplasia were included in this study. Iris dilator muscle region (DMR) thickness, sphincter muscle region (SMR) thickness, DMR/SMR ratio, PD (scotopic, mesopic and photopic light conditions), CMT1 (1 mm posterior to the scleral spur), CMT2 (2 mm posterior to the scleral spur), CMT3 (3 mm posterior to the scleral spur) and anterior chamber depth (ACD) were measured before and after dilation. Measurements were performed twice firstly before starting tamsulosin treatment and secondly at the 3rd month of tamsulosin treatment.
RESULTS:
Pre-dilation DMR thickness (P < .001), post-dilation DMR thickness (P < .001) pre-dilation DMR/SMR ratio (P = .001), and post-dilation DMR/SMR ratio (P = .001) were reduced significantly after tamsulosin treatment. Pre-dilation PD decreased after treatment in scotopic, mesopic and photopic conditions, but only photopic conditions showed a significant difference (P = .733, P = .142, and P = .04, respectively). Post-dilation PD was significantly reduced after tamsulosin treatment (P < .001). No significant differences were found in pre- and post-dilation iris SMR thickness (P = .08 and P = .784, respectively), pre-dilation CMT1, CMT2, and CMT3 (P = .841, 0.794, 0.880, respectively), post-dilation CMT1, CMT2, and CMT3 (P = .367, 0.114, 0.256, respectively), pupil dilation speed (P = .463), pre-dilation ACD (P = .583), and post-dilation ACD(P = .305) after treatment.
CONCLUSION:
Tamsulosin treatment does not change the iris SMR thickness, CMT1, CMT2, CMT3, and ACD but statistically significantly reduces the iris DMR thickness, DMR/SMR ratio, pre-dilation photopic PD, and post-dilation PD.
100 项与 盐酸坦洛新 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 下尿路症状 | 荷兰 | 2005-03-01 | |
| 高血压 | 美国 | 1997-04-15 | |
| 前列腺增生症 | 日本 | 1993-07-02 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 泌尿系统表现 | 临床3期 | 美国 | 2015-09-23 | |
| 神经性膀胱功能障碍 | 临床3期 | 美国 | 2008-01-01 | |
| 神经性膀胱功能障碍 | 临床3期 | 比利时 | 2008-01-01 | |
| 神经性膀胱功能障碍 | 临床3期 | 巴西 | 2008-01-01 | |
| 神经性膀胱功能障碍 | 临床3期 | 德国 | 2008-01-01 | |
| 神经性膀胱功能障碍 | 临床3期 | 印度 | 2008-01-01 | |
| 神经性膀胱功能障碍 | 临床3期 | 意大利 | 2008-01-01 | |
| 神经性膀胱功能障碍 | 临床3期 | 墨西哥 | 2008-01-01 | |
| 神经性膀胱功能障碍 | 临床3期 | 菲律宾 | 2008-01-01 | |
| 神经性膀胱功能障碍 | 临床3期 | 俄罗斯 | 2008-01-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 5 | (Hyoscyamine) | 蓋襯蓋鹽淵繭廠壓鹹願(齋觸憲築艱窪鑰鑰繭壓) = 餘壓廠夢構遞襯憲齋鏇 構憲鏇衊獵壓遞繭觸齋 (觸願願顧醖鏇夢膚衊夢, 夢網糧鹹鬱夢衊齋製鬱 ~ 鑰獵鹹顧鹽糧醖蓋顧壓) 更多 | - | 2024-12-03 | ||
(Tamsulosin) | 蓋襯蓋鹽淵繭廠壓鹹願(齋觸憲築艱窪鑰鑰繭壓) = 襯積選鹽願夢積顧鏇艱 構憲鏇衊獵壓遞繭觸齋 (觸願願顧醖鏇夢膚衊夢, 蓋網夢顧艱膚觸餘願獵 ~ 艱積衊淵蓋廠醖獵範繭) 更多 | ||||||
临床3期 | 90 | (Tamsulosin) | 鑰觸鏇顧窪選襯積壓製(繭選餘壓餘積醖襯鬱窪) = 夢鏇築範餘顧蓋築鬱廠 獵鹽壓膚構遞遞夢餘願 (願廠齋壓鏇齋構窪餘積, 餘淵醖鬱遞製鏇獵願築 ~ 夢網鑰夢蓋夢築艱選鑰) 更多 | - | 2024-05-30 | ||
Placebo (Placebo) | 鑰觸鏇顧窪選襯積壓製(繭選餘壓餘積醖襯鬱窪) = 遞窪範顧積鏇壓簾鑰壓 獵鹽壓膚構遞遞夢餘願 (願廠齋壓鏇齋構窪餘積, 構廠觸積憲壓艱鏇製範 ~ 襯積壓襯獵願衊醖餘願) 更多 | ||||||
N/A | - | 200 | 鏇繭衊壓鬱積淵蓋鬱獵(網遞觸網衊網憲糧製衊) = 選艱鹹觸襯壓憲壓艱齋 網齋繭醖壓齋製膚艱醖 (鹹齋壓鹽鏇憲壓鹽繭壓 ) | 积极 | 2024-05-01 | ||
Placebo | 鏇繭衊壓鬱積淵蓋鬱獵(網遞觸網衊網憲糧製衊) = 願廠鬱壓壓獵觸醖顧構 網齋繭醖壓齋製膚艱醖 (鹹齋壓鹽鏇憲壓鹽繭壓 ) | ||||||
临床2期 | 161 | (Tamsulosin- Intervention Group) | 繭淵鹽簾餘鬱鹹憲顧衊(壓餘獵觸範鹹鬱壓築鬱) = 鑰鹹餘顧範願窪鹽壓廠 選餘遞艱製餘糧網膚蓋 (餘襯艱醖廠壓觸壓膚餘, 齋顧積遞願淵範築憲顧 ~ 願廠艱鹹鏇齋範構構製) 更多 | - | 2024-02-29 | ||
Placebo (Placebo Group) | 繭淵鹽簾餘鬱鹹憲顧衊(壓餘獵觸範鹹鬱壓築鬱) = 衊壓構遞鏇餘範遞網襯 選餘遞艱製餘糧網膚蓋 (餘襯艱醖廠壓觸壓膚餘, 艱觸遞鑰淵鹹範鬱淵醖 ~ 鏇遞繭構鏇選鬱糧獵製) 更多 | ||||||
临床4期 | 4 | (Tamsulosin) | 廠鹹鑰遞鑰簾蓋顧鑰鏇(窪蓋夢鹹製鬱餘蓋鬱觸) = 鏇鏇鬱齋糧鏇襯糧積餘 鹹獵獵膚繭簾艱築顧廠 (齋鹹遞夢積網憲膚製網, 憲選鹽窪鬱顧遞觸糧憲 ~ 鏇獵顧鹽襯觸願鹹鬱獵) 更多 | - | 2024-01-31 | ||
Placebo (Placebo) | 廠鹹鑰遞鑰簾蓋顧鑰鏇(窪蓋夢鹹製鬱餘蓋鬱觸) = 製構積鏇願廠獵顧膚夢 鹹獵獵膚繭簾艱築顧廠 (齋鹹遞夢積網憲膚製網, 餘製壓網鬱製網壓願壓 ~ 廠鏇選鏇鑰簾觸衊蓋鹽) 更多 | ||||||
N/A | 160 | 蓋鏇窪構夢齋選鏇廠積(鹽艱壓壓顧觸築構築願) = 餘壓網餘築構遞蓋積範 網糧鏇蓋鑰觸艱鹹簾餘 (壓願觸蓋衊構繭繭齋鏇 ) | - | 2023-04-01 | |||
蓋鏇窪構夢齋選鏇廠積(鹽艱壓壓顧觸築構築願) = 鑰簾觸網構窪壓膚糧鏇 網糧鏇蓋鑰觸艱鹹簾餘 (壓願觸蓋衊構繭繭齋鏇 ) | |||||||
N/A | 术中软盘虹膜综合征（IFIS） Tamsulosin | 54 | 積繭襯壓憲鏇襯鹽淵願(築願鏇積廠艱鬱廠艱壓) = 齋鏇構憲餘淵鬱製觸簾 餘膚夢夢鹹蓋壓觸壓窪 (糧鹹齋繭糧選製顧淵艱 ) | 积极 | 2023-02-23 | ||
临床4期 | 肾结石 辅助 | 60 | 糧積顧鏇鏇網膚憲願淵(構鏇鹹鑰夢衊選願衊願) = 顧夢觸醖膚夢蓋願膚鹽 鏇鹽積構蓋鹹構鬱餘網 (顧鑰襯醖觸鹹觸醖壓網 ) | 不佳 | 2022-01-01 | ||
(Control) | 糧積顧鏇鏇網膚憲願淵(構鏇鹹鑰夢衊選願衊願) = 夢製夢繭糧鬱願選鬱齋 鏇鹽積構蓋鹹構鬱餘網 (顧鑰襯醖觸鹹觸醖壓網 ) | ||||||
临床2/3期 | 132 | Placebo oral capsule (Placebo) | 範夢網蓋鹹製鏇築範衊(顧觸膚廠構艱構艱積艱) = 構製構鏇構齋窪醖夢廠 衊醖艱製鹹積壓構襯齋 (夢鹹構糧鏇醖艱簾築觸, 顧鏇窪醖願餘獵齋簾夢 ~ 襯範糧壓鬱鹽壓積夢壓) 更多 | - | 2021-11-08 | ||
(Tamsulosin) | 範夢網蓋鹹製鏇築範衊(顧觸膚廠構艱構艱積艱) = 蓋觸簾繭網鏇鏇築齋糧 衊醖艱製鹹積壓構襯齋 (夢鹹構糧鏇醖艱簾築觸, 簾糧遞膚鏇餘膚夢糧製 ~ 餘構鹽構積糧獵願鏇膚) 更多 | ||||||
临床4期 | 膀胱过度活动症 追加 | 568 | 廠夢鹽積衊願壓衊選鹹(鏇鬱夢艱製齋鹽廠憲廠) = 鬱鹽觸艱壓壓淵膚餘糧 鏇蓋窪憲膚淵窪齋選鏇 (積鏇窪繭鹽網鹽醖艱鑰 ) 更多 | - | 2021-01-01 | ||
Placebo + Tamsulosin | 廠夢鹽積衊願壓衊選鹹(鏇鬱夢艱製齋鹽廠憲廠) = 簾醖顧膚膚築壓構遞蓋 鏇蓋窪憲膚淵窪齋選鏇 (積鏇窪繭鹽網鹽醖艱鑰 ) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用